Omnio AB attracts EUR 1.5 million in capital investment and aims for first clinical trials in 2024
The Umeå-based biopharmaceutical company Omnio AB, focusing on wound healing, has received a capital injection of 1.5 million euros from its shareholders, which will be used for ongoing development work and to begin creating a blueprint for manufacturing.